SynthesisJournal of cancer research and clinical oncology2015

Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis.

Min Ying et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.